Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

The major molecular response rate for asciminib at week 156 continued to be higher than with bosutinib.

Kizzie Charles, MS, APRN, AGCNS-BC, CNOR, walks through the process of developing a successful quality improvement project in the perioperative oncology setting.

An initiative led by nurses helped reduce operating-room pressure injuries and saved their institution an estimated $80,210 per year.

Patrimumab deruxtecan garnered a 29.8% overall response rate in pretreated patients with EGFR-mutated non–small cell lung cancer.

Linda Bloom, MPA, RN, OCN, explains how amplifiers and audio interpreter tablets can be vital resources during cancer care.

Oncology nurses across the country are spearheading initiatives to improve education, attitudes, and access surrounding palliative care.

Linda Bloom, MPA, RN, OCN, highlights how tools such as audio interpretation technology and clear masks can help nurses and patients overcome communication barriers in oncology.

Pirtobrutinib was associated with a 19.6-month median progression-free survival in patients with heavily pretreated chronic lymphocytic leukemia and small lymphocytic lymphoma.

Maintenance bevacizumab plus durvalumab and olaparib improved progression-free survival in patients with HRD-negative advanced ovarian cancer.

Yelena Shames, MSA, ACNP-BC, CNRN, argues that frequent hematologic evaluations may not always be warranted with immune checkpoint inhibitors.

Yelena Shames, MSA, ACNP-BC, CNRN, discusses when immune checkpoint inhibitor treatment should be paused because of laboratory abnormalities.

The implementation of a nonpharmacologic pain intervention bundle helped decrease opioid use among patients recovering from gynecologic and urologic surgeries at a comprehensive cancer center.

Linh Nguyen BSN, RN, OCN, BMTCN, highlights the benefits of prospective toxicity data collection for patients undergoing bone marrow transplantation.

Updated findings from the KEYNOTE-146 trial support the use of lenvatinib/pembrolizumab in advanced endometrial cancer.

Oncology nurses provide perspective on the changing standards of care for patients with triple-negative breast cancer.

In an all-randomized population of patients with advanced gastric cancer, gastroesophageal junction, or esophageal adenocarcinoma, adding nivolumab to chemotherapy yielded a 21% reduction in the risk of death.

Heavily pretreated patients with Waldenström macroglobulinemia demonstrated encouraging responses with pirtobrutinib, a non-covalent BTK inhibitor.

Neratinib was associated with a clinical benefit rate of 45.5% among patients with metastatic or recurrent HER2-mutated cervical cancer.

Adding plinabulin to prophylactic pegfilgrastim and antibiotics may help prevent nonengraftment–related febrile neutropenia.

Patients with treatment-naive extensive-stage small cell lung cancer showed encouraging clinical responses with pembrolizumab and etoposide after multiple years of follow-up.

At data cutoff, all treated patients in a phase 2 trial experienced a clinical complete response with single-agent dostarlimab-gxly.

Findings from DESTINY-Breast04 (NCT03734029) support the use of trastuzumab deruxtecan in patients with hormone receptor–positive, HER2-low metastatic breast cancer.

Phase 2 trial findings indicate that cabozantinib plus nivolumab may be effective in treating patients with non-clear cell renal cell carcinoma with papillary histology.

Cognitive therapies were found to be effective for helping cancer survivors with insomnia, but more research is needed for patients actively receiving treatment.

The addition of ublituximab and umbralisib (Ukoniq; U2) to ibrutinib (Imbruvica) demonstrated a 77% undetectable minimal residual disease (uMRD) rate in patients with chronic lymphocytic leukemia.

Very low dose radiation therapy was found to be an effective treatment approach in the palliative setting for patients with indolent non-Hodgkin lymphoma.

Selinexor, an oral selective inhibitor of nuclear export, demonstrated promising efficacy in increasing progression-free survival among women with advanced endometrial cancer.

Pending FDA approval, the dual immunotherapy combination could provide patients with a new treatment option which would not require any further safety requirements prior to initiation.

The 24-month lymphedema rate was 39.4% among Black women, making it the highest incidence rate in any category.

A presentation at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting shared updated findings on the efficacy of lenvatinib plus pembrolizumab in patients with advanced endometrial cancer.